Pharmacokinetics of remifentanil in conscious cats and cats anesthetized with isoflurane

American Journal of Veterinary Research

Volumn 69, Issue 4, 2008, Pages 531-536

  Pypendop, Bruno H ^a   Brosnan, Robert J ^a   Siao, Kristine T ^a   Stanley, Scott D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLURANE; REMIFENTANIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; CAT; CONSCIOUSNESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GENERAL ANESTHESIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; VETERINARY MEDICINE;

ANALGESICS, OPIOID; ANESTHESIA, INHALATION; ANIMALS; AREA UNDER CURVE; CATS; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; ISOFLURANE; PIPERIDINES; RANDOM ALLOCATION;

ANIMALIA;

EID: 42349100407     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.4.531     Document Type: Article

References (39)

1. Glass PS, Gan TJ, Howell S. A review of the pharmacokinetics and pharmacodynamics of remifentanil. Anesth Analg 1999;89: S7-S14.
2. Rosow CE. An overview of remifentanil. Anesth Analg 1999;89: S1-S3.
3. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology 1996;84:812-820.
4. Hoke JF, Shlugman D, Dershwitz M, et al. Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers. Anesthesiology 1997;87:533-541.
5. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 1991;74:53-63.
6. Wilcke JR. Idiosyncracies of drug metabolism in cats. Effects on pharmacotherapeutics in feline practice. Vet Clin North Am Small Anim Pract 1984;14:1345-1354.
7. Ecobichon DJ, Comeau AM. Pseudocholinesterases of mammalian plasma: physicochemical properties and organophosphate inhibition in eleven species. Toxicol Appl Pharmacol 1973;24:92-100.
8. Hobbiger F, Peck AW. Hydrolysis of suxamethonium by different types of plasma. Br J Pharmacol 1969;37:258-271.
9. Voss G, Sachsse K. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylthiocholine-DTNB procedure. Toxicol Appl Pharmacol 1970;16:764-772.
10. Vogt M, Smith AD, Fuenmayor LD. Factors influencing the cholinesterases of cerebrospinal fluid in the anaesthetized cat. Neuroscience 1984;12:979-995.
11. Thomasy SM, Pypendop BH, Ilkiw JE, et al. Pharmacokinetics of lidocaine and its active metabolite, monoethylglycinexylidide, after intravenous administration of lidocaine to awake and isoflurane-anesthetized cats. Am J Vet Res 2005;66:1162-1166.
12. Bender J, van den Elshout J, Selinger K, et al. Determination of remifentanil in human heparinised whole blood by tandem mass spectrometry with short-column separation. J Pharm Biomed Anal 1999;21:559-567.
13. Gibaldi M, Perrier D. Multicompartment models. In: Gibaldi M, ed. Pharmacokinetics. 2nd ed. New York: Marcell Dekker, 1982;45-109.
14. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
15. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 3rd ed. Stockholm: Swedish Pharmaceutical Press, 2002.
16. Chism JP, Rickert DE. The pharmacokinetics and extra-hepatic clearance of remifentanil, a short acting opioid agonist, in male beagle dogs during constant rate infusions. Drug Metab Dispos 1996;24:34-40.
17. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998;89:562-573.
18. Egan TD, Kern SE, Muir KT, et al. Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers. Br J Anaesth 2004;92:335-343.
19. Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993;79:881-892.
20. Egan TD, Minto CF, Hermann DJ, et al. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 1996;84:821-833.
21. Glass PS, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 1993;77:1031-1040.
22. Hoke JF, Cunningham F, James MK, et al. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther 1997;281:226-232.
23. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997;86:10-23.
24. Pitsiu M, Wilmer A, Bodenham A, et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth 2004;92:493-503.
25. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology 1993;79:893-903.
26. Michelsen LG, Holford NH, Lu W, et al. The pharmacokinetics of remifentanil in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Anesth Analg 2001;93:1100-1105.
27. Pascoe PJ. Opioid analgesics. Vet Clin North Am Small Anim Pract 2000;30:757-772.
28. Grand TI. Body weight: its relation to tissue composition, segment distribution, and motor function. I. Interspecific comparisons. Am J Phys Anthropol 1977;47:211-240.
29. Kabbaj M, Vachon P, Varin F. Impact of peripheral elimination on the concentration-effect relationship of remifentanil in anaesthetized dogs. Br J Anaesth 2005;94:357-365.
30. Lee DD, Papich MG, Hardie EM. Comparison of pharmacokinetics of fentanyl after intravenous and transdermal administration in cats. Am J Vet Res 2000;61:672-677.
31. Steffey EP, Howland D, Jr. Isoflurane potency in the dog and cat. Am J Vet Res 1977;38:1833-1836.
32. Klide AM. Cardiopulmonary effects of enflurane and isoflurane in the dog. Am J Vet Res 1976;37:127-131.
33. Hodgson DS, Dunlop CI, Chapman PL, et al. Cardiopulmonary effects of anesthesia induced and maintained with isoflurane in cats. Am J Vet Res 1998;59:182-185.
34. Stewart GN. The output of the heart in dogs. Am J Physiol 1921;57:27-50.
35. Riviere JE. Population pharmacokinetic models and Bayesian forecasting. Comparative pharmacokinetics: principles, techniques, and applications. Ames, Iowa: Iowa State Press, 1999;259-282.
36. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response, in Proceedings. Annu Rev Genomics Hum Genet 2001;2:9-39.
37. Palmer SN, Giesecke NM, Body SC, et al. Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology 2005;102:663-671.
38. La Du B. Plasma esterase activity and the metabolism of drugs with ester groups. Ann N Y Acad Sci 1971;179:684-694.
39. Pantuck EJ. Plasma cholinesterase: gene and variations. Anesth Analg 1993;77:380-386.